Cargando…

RADI-29. BIOLOGIC SUBTYPES OF BREAST CANCER BRAIN METS AS A PREDICTOR OF LOCAL CONTROL AFTER STEREOTACTIC RADIOSURGERY

INTRODUCTION: Brain metastases (BM) are diagnosed in approximately 15% of breast cancer (BC) patients. Biologic subtype is predictive of loco-regional recurrence following breast conserving therapy and/or mastectomy with the highest risk in the ER-/PR-/HER2- (TN) subtype. The aim of this study is to...

Descripción completa

Detalles Bibliográficos
Autores principales: Salgado, Lucas Resende, Smith, Andrew, Cohen, Alexandra, Tseng, Tzu-Chi, Lin, Jung-Yi, Moshier, Erin, Green, Sheryl, Germano, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213163/
http://dx.doi.org/10.1093/noajnl/vdz014.121
_version_ 1783531743820644352
author Salgado, Lucas Resende
Smith, Andrew
Cohen, Alexandra
Tseng, Tzu-Chi
Lin, Jung-Yi
Moshier, Erin
Green, Sheryl
Germano, Isabelle
author_facet Salgado, Lucas Resende
Smith, Andrew
Cohen, Alexandra
Tseng, Tzu-Chi
Lin, Jung-Yi
Moshier, Erin
Green, Sheryl
Germano, Isabelle
author_sort Salgado, Lucas Resende
collection PubMed
description INTRODUCTION: Brain metastases (BM) are diagnosed in approximately 15% of breast cancer (BC) patients. Biologic subtype is predictive of loco-regional recurrence following breast conserving therapy and/or mastectomy with the highest risk in the ER-/PR-/HER2- (TN) subtype. The aim of this study is to determine whether biologic subtype is predictive of local control (LC) in BC patients with BM treated with Stereotactic Radiosurgery (SRS). MATERIALS/METHODS: All patients underwent LINAC-based SRS at our institution. Patients were subdivided into three biologic subtypes: ER+/Her2- (Luminal), Her2+, and TN (Basal). Kaplan Meier method was used to estimate the overall survival (OS). Cox proportional hazard model was used to analyze association of local failure (LF) with biologic subtypes. This is an IRB-approved single center retrospective study. RESULTS: 108 BC BM in 50 consecutive patients were included in this study with a median follow up of 11.1 months. The median disease-specific GPA was 2.0, and all patients received systemic chemotherapy and/or hormonal therapy. The 12 month LC rates for the entire cohort were 85%, 87%,49% for Luminal, Her2+ and Basal, respectively, with a significantly shorter LC for the basal sub-type (p=0.014). The 12 month OS rates were 83%, 88%, 80% for Luminal, Her2+ and Basal, respectively with a no significant difference in OS among the subgroups. 24% of the lesions were treated with salvage whole brain radiation therapy. CONCLUSIONS: This study shows that in BC patients with BM treated with SRS, biologic subtype impacts LC but not OS. Consideration of radiation treatment intensification or altered fractionation to improve LC may be indicated for the TN subtype. Further multi-center studies are necessary to corroborate our results.
format Online
Article
Text
id pubmed-7213163
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72131632020-07-07 RADI-29. BIOLOGIC SUBTYPES OF BREAST CANCER BRAIN METS AS A PREDICTOR OF LOCAL CONTROL AFTER STEREOTACTIC RADIOSURGERY Salgado, Lucas Resende Smith, Andrew Cohen, Alexandra Tseng, Tzu-Chi Lin, Jung-Yi Moshier, Erin Green, Sheryl Germano, Isabelle Neurooncol Adv Abstracts INTRODUCTION: Brain metastases (BM) are diagnosed in approximately 15% of breast cancer (BC) patients. Biologic subtype is predictive of loco-regional recurrence following breast conserving therapy and/or mastectomy with the highest risk in the ER-/PR-/HER2- (TN) subtype. The aim of this study is to determine whether biologic subtype is predictive of local control (LC) in BC patients with BM treated with Stereotactic Radiosurgery (SRS). MATERIALS/METHODS: All patients underwent LINAC-based SRS at our institution. Patients were subdivided into three biologic subtypes: ER+/Her2- (Luminal), Her2+, and TN (Basal). Kaplan Meier method was used to estimate the overall survival (OS). Cox proportional hazard model was used to analyze association of local failure (LF) with biologic subtypes. This is an IRB-approved single center retrospective study. RESULTS: 108 BC BM in 50 consecutive patients were included in this study with a median follow up of 11.1 months. The median disease-specific GPA was 2.0, and all patients received systemic chemotherapy and/or hormonal therapy. The 12 month LC rates for the entire cohort were 85%, 87%,49% for Luminal, Her2+ and Basal, respectively, with a significantly shorter LC for the basal sub-type (p=0.014). The 12 month OS rates were 83%, 88%, 80% for Luminal, Her2+ and Basal, respectively with a no significant difference in OS among the subgroups. 24% of the lesions were treated with salvage whole brain radiation therapy. CONCLUSIONS: This study shows that in BC patients with BM treated with SRS, biologic subtype impacts LC but not OS. Consideration of radiation treatment intensification or altered fractionation to improve LC may be indicated for the TN subtype. Further multi-center studies are necessary to corroborate our results. Oxford University Press 2019-08-12 /pmc/articles/PMC7213163/ http://dx.doi.org/10.1093/noajnl/vdz014.121 Text en © The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Salgado, Lucas Resende
Smith, Andrew
Cohen, Alexandra
Tseng, Tzu-Chi
Lin, Jung-Yi
Moshier, Erin
Green, Sheryl
Germano, Isabelle
RADI-29. BIOLOGIC SUBTYPES OF BREAST CANCER BRAIN METS AS A PREDICTOR OF LOCAL CONTROL AFTER STEREOTACTIC RADIOSURGERY
title RADI-29. BIOLOGIC SUBTYPES OF BREAST CANCER BRAIN METS AS A PREDICTOR OF LOCAL CONTROL AFTER STEREOTACTIC RADIOSURGERY
title_full RADI-29. BIOLOGIC SUBTYPES OF BREAST CANCER BRAIN METS AS A PREDICTOR OF LOCAL CONTROL AFTER STEREOTACTIC RADIOSURGERY
title_fullStr RADI-29. BIOLOGIC SUBTYPES OF BREAST CANCER BRAIN METS AS A PREDICTOR OF LOCAL CONTROL AFTER STEREOTACTIC RADIOSURGERY
title_full_unstemmed RADI-29. BIOLOGIC SUBTYPES OF BREAST CANCER BRAIN METS AS A PREDICTOR OF LOCAL CONTROL AFTER STEREOTACTIC RADIOSURGERY
title_short RADI-29. BIOLOGIC SUBTYPES OF BREAST CANCER BRAIN METS AS A PREDICTOR OF LOCAL CONTROL AFTER STEREOTACTIC RADIOSURGERY
title_sort radi-29. biologic subtypes of breast cancer brain mets as a predictor of local control after stereotactic radiosurgery
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213163/
http://dx.doi.org/10.1093/noajnl/vdz014.121
work_keys_str_mv AT salgadolucasresende radi29biologicsubtypesofbreastcancerbrainmetsasapredictoroflocalcontrolafterstereotacticradiosurgery
AT smithandrew radi29biologicsubtypesofbreastcancerbrainmetsasapredictoroflocalcontrolafterstereotacticradiosurgery
AT cohenalexandra radi29biologicsubtypesofbreastcancerbrainmetsasapredictoroflocalcontrolafterstereotacticradiosurgery
AT tsengtzuchi radi29biologicsubtypesofbreastcancerbrainmetsasapredictoroflocalcontrolafterstereotacticradiosurgery
AT linjungyi radi29biologicsubtypesofbreastcancerbrainmetsasapredictoroflocalcontrolafterstereotacticradiosurgery
AT moshiererin radi29biologicsubtypesofbreastcancerbrainmetsasapredictoroflocalcontrolafterstereotacticradiosurgery
AT greensheryl radi29biologicsubtypesofbreastcancerbrainmetsasapredictoroflocalcontrolafterstereotacticradiosurgery
AT germanoisabelle radi29biologicsubtypesofbreastcancerbrainmetsasapredictoroflocalcontrolafterstereotacticradiosurgery